Early Stage Haste Creates Future Waste: Three Strategies that Integrate Your Value Story

August 23, 2017

In the rush to get an IND filed and issue that all-important “Phase I trial initiated” press release,
many small to mid-size firms end up patching together their clinical and regulatory value story from multiple sources. The result? A collection of development data and information that may lack coherence and, consequently, credibility.

By investing in a coherent value story before and even after filing for an IND, sponsors can take advantage of what may be viewed as a dry run before market. This lays the foundation for greater commercial success whether you intend to develop, out-license, or sell your product.

Integrating clinical and regulatory functions from an early stage adds value to your product, reduces costs (sometimes just by getting to “no” faster), and ultimately produces a sharper, more compelling value story. Here are three strategies we advise clients with early-stage assets to keep in mind.

Previous Flipbook
Smart Strategies for the Beginning and End of Drug Development
Smart Strategies for the Beginning and End of Drug Development

Next Flipbook
Three Ways To Thrive As Regulators Raise The Bar on Data Integrity Requirements
Three Ways To Thrive As Regulators Raise The Bar on Data Integrity Requirements

Take this three-pronged approach to detecting, preventing, and correcting data integrity lapses.